Jump to content [j] Jump to local navigation [l]

NIHR Health Technology Assessment programme

National Institute for Health Research

Direct link to this page: http://www.hta.ac.uk/1031

Details of HTA journal title

Research type:	Primary Research (e.g. trial)
Title (lead author) etc:	A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs The SANAD trial (Marson) 145 pages, Volume 11, number 37
DOI	10.3310/hta11370
View/print executive summary View/print abstract View full text in pdf format (1386 KB) Buy a printed version of this title - cost £20.00 each. [How to order] This title is available on our CD-ROM of the journal. Order a CD-ROM - free of charge worldwide. Outputs from this project Marson, A; Al-Kharusi, A; Alwaidh, M; Appleton, R; Baker, G; Chadwick, D; Cramp, C; Cockerell, O; Cooper, P; Doughty, J; Eaton, B; Gamble, C; Goulding, P; Howell, S; Hughes, A; Jackson, M; Jacoby, A; Kellett, M; Lawson, G; Leach, J; Nicolaides, P; Roberts, R; Shackley, P; Shen, J; Smith, P; Smith, P; Tudur Smith, C; Vanoli, A; Williamson, P. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007; 369(9566):1016-1026. Marson, A; Al-Kharusi, A; Alwaidh, M; Appleton, R; Baker, G; Chadwick, D; Cramp, C; Cockerell, O; Cooper, P; Doughty, J; Eaton, B; Gamble, C; Goulding, P; Howell, S; Hughes, A; Jackson, M; Jacoby, A; Kellett, M; Lawson, G; Leach, J; Nicoladides, P; Roberts, R; Shackley, P; Shen, J; Smith, D; Smith, P; Tudur Smith, C; Vanoli, A; Williamson, P. The SANAD study of effectiveness of carbamazepine, gabapentine, lamotrigine, oxcarbazepine or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 2007; 369(9566):1000-1015. Go to our correspondence page to comment on this publication
Headline:	Trial provides evidence that lamotrigine may be a clinical and cost-effective alternative to the existing standard drug treatment, carbamazepine, for epilepsy patients diagnosed as having partial seizures.
Project ref:	95/13/01
Original project title:	A randomised controlled trial of longer-term clinical outcomes and cost-effectiveness of standard and new antiepileptic drugs (SANAD)
Chief Investigator:	Professor David Chadwick, Professor of Neurology, Dept of Neurological Science, The Walton Centre for Neurology and Neurosurgery
Project Website	http://www.liv.ac.uk/neuroscience/sanad/
Start Date:	September 1998
Date of publication in HTA journal series	October 2007
Cost:	£1,349,657
MeSH* index primary terms:	EPILEPSY Q-drug-therapy; ANTICONVULSANTS Q-therapeutic-use (* = Medical Subject Headings)
MeSH* index secondary terms:	RANDOMIZED-CONTROLLED-TRIAL; CLINICAL-TRIAL; FOLLOW-UP-STUDIES; CARBAMAZEPINE Q-therapeutic-use; VALPROIC-ACID Q-therapeutic-use; COST-BENEFIT-ANALYSIS; TREATMENT-OUTCOME; HUMAN; COMPARATIVE-STUDY (* = Medical Subject Headings)
ISRCTN* number:	ISRCTN 38354748 (International Standard Randomised Controlled Trial Number) URL of this project on the Controlled Trials Website: http://www.controlled-trials.com/ISRCTN38354748*
NRR* number, if applicable:	N0484070422 (*National Research Register) The National Research Register was a public database of ongoing and recently completed research projects funded by, or of interest to, the United Kingdom's National Health Service (NHS). It is now an archive of projects from early 2000 to September 2007. Search the NRR archive.
Project Protocol:	Project protocol not available
Printed copies of this title despatched:	119 (Figures relate to the previous calendar month)
URL of this page:	http://www.hta.ac.uk/1031

Last updated: 1 February 2012 - Next update due: 8 February 2012

What's related:

Useful downloads:

HTA news service:

News feeds